Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma.

about

Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma

P2860

Q57270689-5887BC2E-7044-4487-BAAC-2CB28378FB33

P2860

Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma.

Item

http://www.wikidata.org/entity/Q55010628

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma.

@en

Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma.

@nl

type

Item

label

Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma.

@en

Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma.

@nl

prefLabel

Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma.

@en

Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma.

@nl

P1476

Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma

@en

P2093

Cory Mavis

http://www.w3.org/2001/XMLSchema#string

Francisco Hernandez-Ilizaliturri

http://www.w3.org/2001/XMLSchema#string

Juan Gu

http://www.w3.org/2001/XMLSchema#string

Maria Bhatti

http://www.w3.org/2001/XMLSchema#string

Matthew J Barth

http://www.w3.org/2001/XMLSchema#string

Mitchell S Cairo

http://www.w3.org/2001/XMLSchema#string

Thomas Ippolito

http://www.w3.org/2001/XMLSchema#string

P2860

Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas

A microRNA polycistron as a potential human oncogene

MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.

TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.

Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.

Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study.

Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.

Genome wide copy number analysis of paediatric Burkitt lymphoma using formalin-fixed tissues reveals a subset with gain of chromosome 13q and corresponding miRNA over expression

P304

21820-21830

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.25072

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Megan S Lim

P577

2018-04-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29774105

http://www.w3.org/2001/XMLSchema#string

P921

Burkitt lymphoma

P932

5955151

http://www.w3.org/2001/XMLSchema#string

Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma.

about

P2860

P2860

Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932